Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?
Barbounis
Vassilios
V
Department of Medical Oncology, St Savas Cancer Hospital, Athens, Greece. barbouv@ath.forthnet.gr
D019072:Antibiotic Prophylaxis; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000401:mortality; D045363:Pneumocystis carinii / Q000302:isolation & purification*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011336:Probability; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage*
D015662:Trimethoprim, Sulfamethoxazole Drug Combination